Arjun Vasant Balar

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles et al. · The Lancet · 2016 · 3.7K citations

Medicine, Oncology, Pharmacotherapy +13

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

Arjun Vasant Balar, Matthew D. Galsky, Jonathan E. Rosenberg et al. · The Lancet · 2016 · 2.2K citations · Full text

Medicine, Oncology, Pharmacology +11

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

Arjun Vasant Balar, Daniel Castellano, Peter H. O’Donnell et al. · The Lancet Oncology · 2017 · 1.3K citations

Medicine, Oncology, Pharmacology +12

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

Jonathan E. Rosenberg, Peter H. O’Donnell, Arjun Vasant Balar et al. · Journal of Clinical Oncology · 2019 · 626 citations · Full text

Medicine, Oncology, Pharmacology +17

TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

Scott T. Tagawa, Arjun Vasant Balar, Daniel P. Petrylak et al. · Journal of Clinical Oncology · 2021 · 533 citations · Full text

Medicine, Oncology, Pharmacology +13